FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 06826 | 說明 | H 股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | | | 事件 | 已發行股份（不包括庫存股份）數 ...

证券代码：688366 证券简称：昊海生科 公告编号：2024-049 上海昊海生物科技股份有限公司 关于第二期以集中竞价交易方式回购公司 截至 2024 年 8 月 31 日，公司尚未实施第二期股份回购。 三、 其他事项 | 回购方案首次披露日 | 2024/8/17 | | --- | --- | | 回购方案实施期限 | 自第五届董事会第二十五次会议审议通过后 12 个 | | | 月 | | 预计回购金额 | 10,000.00 万元~20,000.00 万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 0 股 | | 累计已回购股数占总股本比例 | 0% | | 累计已回购金额 | 0 万元 | | 实际回购价格区间 | 0 元/股~0 元/股 | 一、 回购股份的基本情况 上海昊海生物科技股份有限公司（以下简称"公司"）于 2024 年 8 月 16 日召 开第五届董事会第二十五次会议审议通过了《关于第二期以集中竞价交易方式回 购公司 A 股股份方案的议案》，同意公司以集中 ...

Financial Performance - For the six months ended June 30, 2024, the company recorded revenue of approximately RMB 1,397.11 million, an increase of approximately RMB 91.40 million or 7.00% compared to RMB 1,305.71 million in the same period of 2023[9]. - Profit attributable to ordinary equity holders was approximately RMB 235.28 million, an increase of approximately RMB 30.04 million or 14.64% from RMB 205.24 million in the same period of 2023[9]. - Basic earnings per share for the period were RMB 1.01, compared to RMB 0.86 in the same period of 2023[9]. - The group reported a revenue of approximately RMB 1,397.11 million for the reporting period, an increase of RMB 91.40 million or 7.00% compared to RMB 1,305.71 million in the same period of 2023[38]. - Total comprehensive income for the six months ended June 30, 2024, was RMB 196,737,000, a decrease of 21.2% from RMB 249,563,000 in the same period of 2023[57]. - The profit attributable to equity holders of the parent company increased to RMB 235,283,000, up 14.6% from RMB 205,235,000 year-on-year[57]. - The group’s profit before tax for the six months ended June 30, 2024, was RMB 235,283,000, compared to RMB 205,235,000 for the same period in 2023, representing an increase of approximately 14.6%[84]. Revenue Breakdown - Revenue from the medical beauty and wound care product line was RMB 631.82 million, accounting for 45.22% of total revenue, with a year-on-year growth of 25.53%[11]. - Revenue from ophthalmic products was RMB 449.66 million, accounting for 32.18% of total revenue, showing a decline of 6.15% year-on-year[11]. - Revenue from orthopedic products was RMB 231.82 million, accounting for 16.59% of total revenue, with a slight increase of 0.28% year-on-year[11]. - Revenue from anti-adhesion and hemostatic products was RMB 68.87 million, accounting for 4.93% of total revenue, with a decline of 2.55% year-on-year[11]. - Revenue from the mainland China market was RMB 1,179,576 thousand, an increase of 11.3% from RMB 1,059,733 thousand in the previous year[71]. Research and Development - Research and development expenses for the period were approximately RMB 125.40 million, up by approximately RMB 24.01 million or 23.68% year-on-year, representing 8.98% of total revenue compared to 7.77% in 2023[9]. - The clinical trials for several key R&D projects progressed smoothly during the reporting period, including new high-oxygen contact lens products[12]. - The company continues to focus on the production and sales of bioproducts, medical-grade hyaluronic acid, and artificial lenses, with ongoing R&D in biotechnology and pharmaceuticals[70]. - Research and development costs increased to RMB 125,400,000 for the six months ended June 30, 2024, from RMB 101,391,000 in the same period of 2023, reflecting a growth of about 23.7%[78]. Dividends and Shareholder Returns - The board proposed an interim dividend of RMB 0.40 per share (tax included) for the six months ended June 30, 2024, compared to no dividend in the same period of 2023[9]. - The company proposed an interim dividend of RMB 0.40 per ordinary share, totaling RMB 93,192,000, compared to no dividend for the same period in 2023[82]. Market Position and Growth - The market share of the epidermal growth factor product "Kanghesu" was 26.91% in 2023, maintaining the second position in the domestic market[13]. - The company plans to expand the application of its epidermal growth factor product to multiple departments beyond traditional uses, enhancing its market reach[18]. - The Chinese medical aesthetics market is expected to grow by approximately 10% in 2024, with a compound annual growth rate of 10-15% over the next four years[17]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2025[154]. Cash Flow and Financial Position - Operating cash flow for the six months ended June 30, 2024, was RMB 380,712,000, an increase of 17.1% from RMB 325,038,000 in the same period of 2023[64]. - Cash and cash equivalents as of June 30, 2024, were approximately RMB 924.21 million, an increase of RMB 354.89 million from approximately RMB 569.32 million as of December 31, 2023[51]. - Total current assets as of June 30, 2024, were approximately RMB 3,720.36 million, a decrease of RMB 29.78 million or 0.79% from December 31, 2023[44]. - Total liabilities as of June 30, 2024, were approximately RMB 1,186.37 million, with a debt-to-asset ratio of 16.38%, an increase of 1.07 percentage points from 15.31% as of December 31, 2023[50]. Acquisitions and Investments - The company acquired 51% of Shanghai Shenhao Mijian Technology Development Co., Ltd. for a total consideration of RMB 36.2885 million, completed in June 2024[28]. - The cash outflow from investing activities related to the acquisition of Shenhao Mijian was RMB 16,009,000 after accounting for cash acquired[106]. Corporate Governance and Compliance - The interim financial report was approved by the board on August 16, 2024, and published on the Hong Kong Stock Exchange website[123]. - The company has complied with all applicable code provisions under the Corporate Governance Code during the reporting period[146]. - There were no significant legal proceedings or arbitrations involving the company during the reporting period[150]. Employee Compensation and Incentives - Employee compensation for the reporting period totaled approximately RMB 337.30 million, an increase of RMB 21.77 million from approximately RMB 315.53 million in the same period of 2023[46]. - The company has granted a total of 1,800,000 restricted shares under the 2021 A-share incentive plan, with the first vesting period completed[137]. - Total remuneration for key management personnel amounted to RMB 4,447,000 for the six months ended June 30, 2024, compared to RMB 3,471,000 for the same period in 2023, representing an increase of 28.1%[111].

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 1). | 於 2024 年8月20日回購股份但尚未註銷 | | 102,100 | % | HKD | 28.9 | | --- | --- | --- | --- | --- | --- | --- | | | 變動日期 | 2024年8月20日 | | | | | | 2). | 於 2024 年8月21日回購股份但尚未註銷 | | 52,500 | % | HKD | 29.29 | | | 變動日期 | 2024年8月21日 | | | | | | 3). | 於 2024 年8月22日回購股份但尚未註銷 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 06826 | 說明 | H 股 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 ...

第 1 頁 共 8 頁 v 1.3.0 呈交日期： 2024年8月27日 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06826 | 說明 H 股 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海昊海生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 呈交日期： 2024年8月26日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | | 普通股 | 股份類別 H | | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | | 06826 | 說明 H 股 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 事件 | | 已發行股份（不包括庫 ...

Group 1: Hyaluronic Acid Product Performance - The company's hyaluronic acid products maintained good growth despite a challenging market, with "Hai Mei" leading in market share and high-value product positioning [2] - The new product "Hai Mei Yue Bai" is expected to differentiate itself in the market and is currently completing production licensing [2] - The global hyaluronic acid market shows significant potential, with injection products holding an 80% market share, indicating strong safety and efficacy recognition [2] Group 2: Customization and Sales Strategy - The company aims to balance self-branded products with customized offerings to meet the diverse needs of medical beauty institutions [2] - The current marketing team for medical beauty products consists of approximately 150 to 200 people, with plans to expand to 200 to 250 to match sales growth [2] Group 3: Research and Development Focus - R&D expenses for the first half of 2024 reached 125 million CNY, a 24% increase year-on-year, accounting for 8.93% of revenue [2] - The company is focusing on a full product line and industry chain participation, including products like botulinum toxin and hydroxyapatite [3] Group 4: Market Dynamics and Pricing Strategy - The gross margin for hyaluronic acid products remains around 70%, with a slight decline compared to the previous year due to balancing high and low-margin products [3] - The company is adopting strategies for overseas expansion through acquisitions and brand development, particularly in the medical aesthetics sector [3] Group 5: Crystal Product Sales and Market Trends - Crystal product revenue declined by 10% in the first half of the year, influenced by pricing adjustments from national procurement [4] - The company anticipates an increase in mid-to-high-end product usage as national procurement progresses, which will positively impact overall revenue and profit margins [4] Group 6: Sales and Marketing Efficiency - The sales expense ratio has decreased, primarily due to reduced promotional costs in ophthalmology, orthopedics, and surgery [4] - The company plans to leverage new product launches to drive market promotion without significantly increasing the overall marketing budget [4]

关于注销已回购 H 股股份的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本次回购的基本情况 上海昊海生物科技股份有限公司（以下简称"公司"）于 2024 年 5 月 29 日 召开的 2023 年度股东周年大会、2024 年第一次 A 股类别股东大会及 2024 年第 一次 H 股类别股东大会审议通过了《关于授予董事会回购 H 股的一般性授权的 议案》。 证券代码：688366 证券简称：昊海生科 公告编号：2024-048 上海昊海生物科技股份有限公司 2024 年 8 月 26 日，公司已完成注销本次回购的 493,900 股 H 股股份。上述 注销完成后，公司的总股本由 235,489,895 股变更为 234,995,995 股。公司董事会 将根据股东大会的授权，按照相关程序修改公司章程，并依法办理相关工商变更 登记手续。 三、本次注销完成后的股本结构情况 | | 股份类别 | 本次注销前 | | 本次注销后 | | | --- | --- | --- | --- | --- | --- | | | ...

证券代码：688366 证券简称：昊海生科 上海昊海生物科技股份有限公司 2024 年第一次临时股东大会、 2024 年第二次 A 股类别股东大会 及 2024 年第二次 H 股类别股东大会 会议资料 二〇二四年九月十三日·上海 1 | 会议须知 1 | | --- | | 会议议程 3 | | 关于公司 2024 年半年度利润分配预案的议案 5 | | 关于修订《上海昊海生物科技股份有限公司关联交易管理制度》的议案 7 | | 关于修订《上海昊海生物科技股份有限公司对外担保管理制度》的议案 8 | | 关于修订《上海昊海生物科技股份有限公司防范大股东及关联方占用公司资金专 | | 项制度》的议案 9 | | 关于修订《上海昊海生物科技股份有限公司募集资金管理制度》的议案 10 | | 关于变更公司注册资本并修订公司章程的议案 11 | 上海昊海生物科技股份有限公司 2024 年第一次临时股东大会、2024 年第二次 A 股类别股东大 会及 2024 年第二次 H 股类别股东大会 会议须知 为了维护全体股东的合法权益、确保股东大会的正常秩序和议事效率，保证 股东大会的顺利进行，上海昊海生物科技股份有限公司（以 ...